ArticleThe Journal of urology2014
Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men.
Article in The Journal of urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 10 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2022Pooled it
- Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2021Pooled it
- Lower Urinary Tract Symptoms and Sexual Dysfunction in Male: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2020Pooled it
- Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2020Pooled it
- Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2019Pooled it
- Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2019Pooled it
- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2018Pooled it
- Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2017Pooled it
- The effect of testosterone therapy on erectile dysfunction in type 2 diabetic patients.International urology and nephrology · 2026Trial
- Serum low density lipoprotein cholesterol / high density lipoprotein cholesterol ratio predicts lower urinary tract dysfunction related dyslipidemia.Fukushima journal of medical science · 2025Article
- A cross-tissue transcriptome-wide association study identifies new susceptibility genes for benign prostatic hyperplasia.Scientific reports · 2025Article
- Circulating levels of blood biomarkers and risk of benign prostatic hyperplasia: Results from two large cohorts in Europe and East Asia.Journal of global health · 2024Article
- Approach the Patient With Obstructive Sleep Apnea and Obesity.The Journal of clinical endocrinology and metabolism · 2024Article
- Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement.The Cochrane database of systematic reviews · 2023Review
- Maximum Voided Volume Is a Better Clinical Parameter for Bladder Capacity Than Maximum Cystometric Capacity in Patients With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: A Prospective Cohort Study.International neurourology journal · 2022Article
- Association between life-style, metabolic syndrome and lower urinary tract symptoms and its impact on quality of life in men ≥ 40 years.Scientific reports · 2022Article
- The Translational Role of Animal Models for Estrogen-Related Functional Bladder Outlet Obstruction and Prostatic Inflammation.Veterinary sciences · 2022Review
- Relationship between serum total testosterone and prostate volume in aging men.Scientific reports · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe determined the metabolic, lifestyle and physical factors associated with progression or improvement of storage and voiding lower urinary tract symptoms in a population based cohort of men. MATERIALS AND
methodsAfter the exclusion of men with prostate or bladder cancer and/or surgery from the study, progression and improvement of storage and voiding lower urinary tract symptoms was assessed using the AUA-SI (American Urological Association symptom index) in 780 men, age 35 to 80 years at baseline, who attended 5-year followup clinics.
resultsStorage and voiding lower urinary tract symptoms progressed in 39.8% (308) and 32.3% (250) of men, and improved in 33.1% (256) and 23.4% (181), respectively. In final adjusted regression models greater bother and physical activity at baseline predicted improvement in storage and voiding lower urinary tract symptoms, while greater income, high-density lipoprotein cholesterol and lower triglycerides predicted improvement of storage lower urinary tract symptoms only. Being widowed, higher plasma estradiol and depression at baseline predicted the progression of storage and voiding lower urinary tract symptoms, while greater abdominal fat mass and obstructive sleep apnea risk predicted the progression of storage lower urinary tract symptoms only. Older age, lower high-density lipoprotein cholesterol, testosterone, income, previous benign prostatic hyperplasia and erectile dysfunction at baseline predicted the progression of voiding lower urinary tract symptoms only. The initiation or continued use of α-blockers or anticholinergics (storage lower urinary tract symptoms), and 5α-reductase inhibitors (voiding lower urinary tract symptoms), were associated with symptom improvement.
conclusionsLower urinary tract symptoms may progress or remit. Even accounting for medication use, progression may be associated with modifiable disease, or metabolic or behavioral factors, which are also risk factors for type 2 diabetes and cardiovascular disease. These factors should be looked for and managed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.